Viridian reports positive phase 1 data for VRDN-008, an FcRn inhibitorNov 9Clinical readoutViridian Therapeutics, Inc.\DE
Viridian reports $24.7M in Lumvoa sales in launch quarter, BLA for elegrobart on track for Q1 2027Nov 4Quarterly updateveligrotugViridian Therapeutics, Inc.\DE
Viridian reports Q2 2026 results as Lumvoa launch begins in the U.S.Aug 6Quarterly updateveligrotugViridian Therapeutics, Inc.\DE
FDA approves Viridian's Lumvoa for thyroid eye diseaseJun 26Regulatory decisionveligrotugViridian Therapeutics, Inc.\DE